Moreover, since high expression of GRP78/BiP protect cancer cells from the cytotoxic effects of several chemotherapeutic agents [26, 27], targeting ERMP1 could also weaken GRP78/BiP-dependent chemoresistance mechanisms of cancer cells. Here, HSPA5 is linked to cancer.